Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors

Ann Oncol. 2023 Aug 17:S0923-7534(23)00799-8. doi: 10.1016/j.annonc.2023.08.002. Online ahead of print.NO ABSTRACTPMID:37597581 | DOI:10.1016/j.annonc.2023.08.002

Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: O Adotevi Source Type: research